You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-8 of 8 results found

Vaccines for HIV

The development of an effective HIV vaccine has been an ongoing area of research. The high variability in HIV-1 virus strains has represented a major challenge in successful development. Ideally, an effective candidate vaccine would provide protection against the majority of clades of HIV. Two major hurdles to overcome are immunodominance and sequence diversity. This vaccine utilizes a strategy for overcoming these two issues by identifying the conserved regions of the virus and exploiting them for use in a targeted therapy. NCI seeks licensees and/or research collaborators to commercialize this technology, which has been validated in macaque models.
  • Vaccines

Method for Targeted Therapeutic Delivery of Proteins into Cells

The Protein Expression Laboratory at the National Cancer Institute in Frederick, MD is seeking statements of capability or interest from parties interested in collaborative research to further develop a platform technology for the targeted intra-cellular delivery of proteins using virus-like particles (VLPs).
  • Therapeutics
  • Vaccines
  • Devices

Brachyury-directed Vaccine for the Prevention or Treatment of Cancers

Researchers at the NCI have developed a vaccine technology that stimulates the immune system to selectively destroy metastasizing cells. Stimulation of T cells with the Brachyury peptide promote a robust immune response and lead to targeted lysis of invasive tumor cells. NCI seeks licensing or co-development of this invention.
  • Therapeutics
  • Vaccines

Multi-epitope Vaccines against TARP (ME-TARP) for Treating Prostate and Breast Cancer

Researchers at the NCI have developed a treatment for prostate and breast cancer using multivalent peptides derived from TARP, the T cell receptor gamma alternate reading frame protein. These immunogenic peptides from TARP elicit an immune response, triggering T cells to kill only the cancer cells within a patient. NCI seeks licensees or co-development partners to commercialize this invention.
  • Therapeutics
  • Vaccines

Enhanced Immunogenicity Against HIV-1 Using a DNA-prime Poxvirus Vaccination

Researchers at the National Cancer Institute (NCI) seek research co-development or licenses for a method of stimulating an immune response in a human at risk for infection by, or already infected with, an HIV-1 retrovirus. This method utilizes DNA vaccines to stimulate CD8+ T cell immune responses.
  • Vaccines

Immunogens for Use in a High Efficacy HIV Vaccine

Prevention and control of human immunodeficiency virus (HIV) infections require a vaccine providing long-lasting protection. The most promising vaccine up to date consists of a regimen of immunization with genetically engineered HIV proteins, including the surface glycoprotein gp120, with a resulting efficacy of ~30%. Recent evidence indicates antibodies produced against variable envelope region 2 (V2) of gp120 in primates are associated with higher levels of protection, while antibodies produced against variable envelope region 1 (V1) have an opposite and interfering effect. Researchers at the National Cancer Institute (NCI) and New York University (NYU) have developed V1-deleted gp120 immunogens using Simian immunodeficiency virus (SIV), and observed an increase in antibodies against V2 in macaques upon immunization. NCI is seeking parties interested in co-developing and/or licensing V1-deleted gp120 immunogens for their use in an improved HIV vaccine.
  • Vaccines

Adjuvanted Mucosal Subunit Vaccines for Preventing SARS-CoV-2 Transmission and Infection

Investigators at the National Cancer Institute (NCI) have discovered an adjuvanted mucosal subunit vaccine to prevent SARS-CoV-2 transmission and infection. The mucosal vaccine is composed of a novel molecular adjuvant nanoparticle that induces robust humoral and cellular immunity, as well as trained innate immunity with enhanced protection against respiratory SARS-CoV-2 exposure. The technology is available for potential licensing or collaborative research to co-develop these therapeutic targets.
  • Therapeutics
  • Vaccines

High Efficacy Vaccine and Microbicide Combination For Use Against HIV

The development of a vaccine against human immunodeficiency virus (HIV) would be expected to provide long-lasting protection. Researchers at the National Cancer Institute (NCI) developed a high efficacy vaccine and microbicide combination for use in an improved HIV vaccine regimen.
  • Vaccines